Prof. Andrew Griffiths
Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris and formerly the holder of a Chaire d'Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg.
After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he
joined Greg Winter at the MRC
Laboratory of Molecular Biology (LMB), Cambridge where he
co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995).
This work led directly to the creation of two companies, Cambridge Antibody Technology
(acquired by AstraZeneca
for $1.32 billion) and Domantis (acquired by GSK
for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®.
current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications.
Andrew is a founder of RainDance Technologies.